To which extent is the clinical use of dextran, gelatin and hydroxyethyl starch influenced by the incidence and severity of anaphylactoid reactions?
D000707:Anaphylaxis / Q000139:chemically induced*; D003911:Dextrans / Q000009:adverse effects / Q000627:therapeutic use*; D005780:Gelatin / Q000009:adverse effects / Q000627:therapeutic use*; D006470:Hemorrhage / Q000628:therapy; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives / Q000009:adverse effects / Q000627:therapeutic use*; D012769:Shock / Q000628:therapy; D013213:Starch / Q000031:analogs & derivatives*; D014947:Wounds and Injuries / Q000628:therapy
D003911:Dextrans; D006895:Hydroxyethyl Starch Derivatives; D005780:Gelatin; D013213:Starch